CP Scorecard
Derived from Current Agreements, the partnering scorecard gives an instant overview of the top partnering deals in the life sciences by year.
The following article contains a snapshot of the largest deals by value for the year.
Our Current Agreements database stores and categorizes deal data dating as far back as 2000 saving you valuable time on your deal making research activities.
Searching for more deal information? Current Partnering offers the following options:
|
Top partnering deals of 2024 valued at over US$500m.
Partners | Date | Value, US$m | Subject | Termsheet |
---|---|---|---|---|
MOMA Therapeutics, Roche | Jan 2024 | 2066 | Collaboration and licensing agreement for KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival | MOMA Therapeutics announced a strategic collaboration and licensing agreement with Roche. This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival. MOMA will receive $66 million as an upfront cash payment and is also eligible to receive discovery, development, and commercialization milestone payments potentially exceeding US$2 billion, as well as tiered royalties. MOMA will be primarily responsible for all activities for selected targets through to development candidate confirmation, whereas Roche will be responsible for IND-enabling activities and clinical development and commercialization. Additionally, if multiple collaboration assets reach pivotal clinical studies, MOMA will receive a right to co-fund late-stage development of one product in exchange for increased royalties in the US on this product. |
Boehringer Ingelheim, Suzhou Ribo Life Sciences | Jan 2024 | 2000 | Collaboration and licensing agreement for treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis | Suzhou Ribo Life Science and Ribocure Pharmaceuticals announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis. The partnership brings together Ribo’s leading experience in the discovery and clinical development of small interfering RNA therapeutics with Boehringer’s commitment to improving the lives of people living with cardiovascular, renal and metabolic diseases. Ribo will receive an upfront payment. In this multi-target collaboration, Ribo is entitled to receiving success-based milestones for clinical, regulatory, and commercial success and tiered royalties with an overall deal value that exceeds USD 2 billion. |
Ipsen, Skyhawk Therapeutics | Apr 2024 | 1800 | Option and licensing agreement for small molecules that modulate RNA for rare neurological diseases | Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases Agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates Ipsen will be responsible for all activities Skyhawk is eligible to receive up to $1.8 billion in development, regulatory and commercial milestones, including an upfront payment, for the option and research collaboration, plus potential for tiered royalties |
Eli Lilly, Isomorphic Labs | Jan 2024 | 1745 | Collaboration agreement to discover small molecule therapeutics against multiple targets | Isomorphic Labs has entered into a strategic research collaboration with Eli Lilly and Company. This marks Isomorphic Labs' first pharmaceutical partnership. Isomorphic Labs will partner with Lilly to discover small molecule therapeutics against multiple targets and will receive an upfront cash payment of $45 million. Isomorphic Labs is eligible to receive up to $1.7 billion in performance-based milestone payments, excluding the upfront payment and any subsequent tiered royalties of up to low double digits on net sales. |
Eli Lilly, Isomorphic Labs | Jan 2024 | 1700 | Collaboration agreement for small molecule therapeutics against multiple targets | Isomorphic Labs has entered into a strategic research collaboration with Eli Lilly. Isomorphic Labs will partner with Lilly to discover small molecule therapeutics against multiple targets and will receive an upfront cash payment of $45 million. Isomorphic Labs is eligible to receive up to $1.7 billion in performance-based milestone payments, excluding the upfront payment and any subsequent tiered royalties of up to low double digits on net sales. |
Gilead Sciences, Merus | Mar 2024 | 1581 | Research and licensing agreement for discovery of novel antibody-based trispecific T-Cell engagers | Gilead Sciences announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens targeting trispecific antibodies. Gilead and Merus agreed to collaborate on the use of Merus’ proprietary Triclonics platform along with Gilead’s oncology expertise to research and develop multiple, separate preclinical research programs. Merus will lead early-stage research activities for two programs, with an option to pursue a third. Gilead will have the right to license programs developed under the collaboration after the completion of select research activities. If Gilead exercises its option to license any such program from the collaboration, Gilead will be responsible for additional research, development and commercialization activities for such program. Merus will receive an upfront cash payment of $56 million for initial targets as well as an equity investment by Gilead of $25 million in Merus common shares. Merus is also eligible to receive up to $1.5 billion including additional near term and option payments, potential development and commercialization milestones, as well as tiered royalties ranging from the mid-single to low-double digits on product sales should Gilead successfully commercialize a therapy from the collaboration. Merus may opt-in to share 50/50 split of net profits and net losses, in lieu of future milestone and royalty payments. Gilead does not exclude acquired IPR&D expenses from its non-GAAP financial measures. This transaction with Merus is expected to reduce Gilead’s GAAP and non-GAAP 2024 EPS by approximately $0.03 - $0.05. |
Neomorph, Novo Nordisk | Feb 2024 | 1460 | Collaboration and licensing agreement for molecular glue degraders for cardiometabolic and rare diseases | Neomorph has entered into a collaboration and licensing agreement with Novo Nordisk to discover, develop and commercialize molecular glue degraders. Neomorph will receive an upfront and near-term milestone payments, plus R&D funding. Neomorph is also eligible to receive future clinical, commercial and sales milestone payments bringing the total potential deal value for multiple targets to $1.46B, plus tiered royalties. Neomorph will lead discovery and preclinical activities against selected targets with Novo Nordisk having the right to exclusively pursue further clinical development and commercialization of the compounds. |
Abbvie, Umoja Biopharma | Jan 2024 | 1440 | Collaboration, option and licensing agreement for in-situ CAR-T cell therapies | AbbVie and Umoja Biopharma announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja's proprietary VivoVec platform. The first agreement provides AbbVie an exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy candidates. This includes UB-VV111, Umoja's lead clinical program for hematologic malignancies currently at the IND-enabling phase. AbbVie and Umoja will develop up to four additional in-situ generated CAR-T cell therapy candidates for discovery targets selected by AbbVie. Umoja received upfront payments and an equity investment from AbbVie. Additionally, for the two agreements combined, Umoja may be eligible to receive up to $1.44B in aggregate for option exercise fees, development and regulatory milestones, with the potential for Umoja to earn additional sales-based milestones and tiered royalties on worldwide net sales. |
Caris Life Sciences, Merck KGaA | Apr 2024 | 1400 | Licensing agreement for discovery of cancer targets and acceleration of antibody drug conjugate development | Caris Discovery announced a multi-year strategic partnership with Merck KGaA to accelerate the discovery and development of first-in-class antibody-drug conjugates for cancer patients Merck KGaA will provide Caris with an upfront payment as well as research funding Caris will be eligible for discovery, development, regulatory and sales-based milestone payments that may total up to $1.4 billion along with tiered royalties Merck KGaA will receive an exclusive global license to develop, manufacture and commercialize ADC therapeutics for selected targets Targets discovered and validated by Caris can be pursued by Merck KGaA Merck will be responsible for the preclinical and clinical research, as well as the development and commercialization of drug candidates emanating from these programs |
Kumquat Biosciences, Takeda Pharmaceutical | Apr 2024 | 1330 | Licensing and development agreement for immuno-oncology small molecule inhibitor | Kumquat Biosciences announced a strategic and exclusive collaboration with Takeda to develop and commercialize a novel immuno-oncology small molecule inhibitor as a mono- and/or combination-therapy Kumquat granted Takeda an exclusive, global, and royalty bearing license to develop and commercialize a selected small molecule inhibitor Subject to Kumquat's option, Takeda will assume and fund all development and commercialization activities beyond the phase 1 trial activities led by Kumquat Kumquat will receive up to $130 million in near-term payments and potentially more than $1.2 billion if all future clinical, regulatory, and commercial milestones are achieved during the term of the agreement Tiered royalties on potential net sales of any commercial products resulting from this license |
Elanco, Merck Animal Health | Feb 2024 | 1300 | Asset purchase agreement for aqua business | Merck Animal Health has signed a definitive agreement to acquire the aqua business of Elanco Animal Health for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. The acquisition is expected to be completed by mid-year 2024, subject to approvals from regulatory authorities and other customary closing conditions. |
Isomorphic Labs, Novartis | Jan 2024 | 1237.5 | Collaboration agreement for small molecule therapeutics against three undisclosed targets | Isomorphic Labs has entered into a strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets. Isomorphic Labs will receive an upfront payment of $37.5 million from Novartis, in addition to Novartis funding of select research costs. Isomorphic Labs is eligible to receive up to $1.2 billion in performance-based milestone payments, excluding the upfront payment and any subsequent tiered royalties from mid-single up to low double-digit royalties on net sales. |
Genentech, Lonza, Roche | Mar 2024 | 1200 | Asset agreement for Genentech manufacturing facility in Vacaville (US) from Roche | Lonza has signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 billion in cash Vacaville (US) site is one of the largest biologics manufacturing facilities in the world by volume Acquisition is set to increase Lonza’s large-scale biologics manufacturing capacity for mammalian therapies and significantly extend the presence of its facility network in the US Lonza plans to invest approximately CHF 500 million to upgrade the facility and enhance capabilities at the site to accommodate the next generation of mammalian biologics therapies Roche products currently manufactured at the site will be supplied by Lonza, with committed volumes over the medium term, phasing out as the site transitions to serve alternative customers |
Arvinas, Novartis | Apr 2024 | 1160 | Licensing agreement for PROTAC androgen receptor protein degrader ARV-766 | Arvinas enters into a transaction with Novartis, including a global license agreement for the development and commercialization of PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program Potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones as well as tiered royalties Novartis to be responsible for worldwide clinical development and commercialization of ARV-766 Partnership expected to accelerate and broaden the development of ARV-766 as a potential first-in-class treatment option for patients with prostate cancer |
MediLink Therapeutics, Roche | Jan 2024 | 1050 | Collaboration and licensing agreement for next-generation antibody drug conjugate in oncology | MediLink Therapeutics has entered into a worldwide collaboration and license agreement with Roche on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors. MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink's ADC asset, YL211. MediLink will work together with Roche's R&D unit China Innovation Center of Roche to initiate the Phase I clinical trial of YL211 and Roche will then take over the further development and commercialization globally. MediLink will receive upfront and near-term milestone payments totaling $50 million and, together with additional development, regulatory and commercial milestone payments potentially reaching a total deal value nearing $1 billion, as well as tiered royalties on future global annual net sales. |
Remix Therapeutics, Roche | Jan 2024 | 1042 | Collaboration agreement for small molecule therapeutics modulating RNA processing | Remix Therapeutics announced a collaboration and license agreement with Roche for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform. Remix will receive an upfront payment of $30 million and are eligible to receive up to $12 million in near-term milestone payments, as well as preclinical, clinical, commercial and sales milestones of up to $1 billion and tiered royalties. Roche will have exclusive rights to specific targets. Remix will conduct discovery and preclinical activities with Roche, and Roche will be responsible for development and commercialization of any resulting products. |
Allorion Therapeutics, Avenzo Therapeutics | Jan 2024 | 1000 | Licensing and option agreement for AVZO-021 | Avenzo Therapeutics has entered into an exclusive licensing agreement with Allorion Therapeutics to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 selective inhibitor globally (excluding Greater China). Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025. Allorion will receive an upfront payment of $40 million and be eligible to receive additional payments based on achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Avenzo. Potential payments for both programs may total more than $1 billion. |
Merck and Co, Pearl Bio | Mar 2024 | 1000 | Licensing and option agreement for discovery and development of biologic therapies for the treatment of cancer | The collaboration will initially focus on discovery and development of biologic therapies for the treatment of cancer leveraging Pearl’s exclusive GRO technology, unique ability to work in both cell-based and cell-free systems and proprietary tethered ribosomes to encode synthetic monomers and target previously inaccessible epitopes. Pearl is eligible to receive payments totaling up to $1B across upfront, option and milestone payments in addition to potential royalties on sales of approved products derived from the collaboration |
Boehringer Ingelheim, Ochre Bio | Apr 2024 | 1000 | Development and licensing agreement for treatments for chronic liver diseases | Ochre Bio announces partnership with Boehringer Ingelheim to develop regenerative treatments for patients with advanced liver disease Multiple targets to be investigated during the course of a multi-year collaboration Ochre Bio will receive up to USD 35 million in upfront and near-term research-based milestone payments Ochre may also receive milestones for clinical, regulatory, and commercial success as well as tiered royalties with an overall deal value with the potential to exceed USD 1 billion |
Ipsen, Sutro Biopharma | Apr 2024 | 900 | Licensing agreement for antibody-drug conjugate, STRO-003 | Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors The agreement gives Ipsen exclusive worldwide rights to develop and commercialize STRO-003 Ipsen will assume responsibility for Phase I preparation activities, including submission of the Investigational New Drug application, and all subsequent clinical-development activities and global commercialization activities Sutro Biopharma is eligible to receive up to $900m in potential upfront, development, regulatory and commercial milestone payments including approximately $90m in near-term payments, including an equity investment, and tiered royalties on global sales, contingent upon successful development and commercialization |
Jazz Pharmaceuticals, Redx Pharma | Feb 2024 | 880 | Collaboration and licensing agreement for KRAS (Kirsten rat sarcoma virus) inhibitor program | Jazz Pharmaceuticals and Redx Pharma have signed a definitive agreement under which Jazz will acquire Redx's KRAS (Kirsten rat sarcoma virus) inhibitor program. Jazz and Redx will collaborate to advance candidates through IND-enabling studies; Jazz will be responsible for all clinical development, regulatory, manufacturing and commercialization activities. Jazz will make an upfront payment to Redx of $10 million for all rights, patents, title and interest relating to Redx's proprietary KRAS inhibitor program, which includes G12D selective and pan-KRAS molecules. Redx is eligible to receive up to $870 million in development, regulatory and commercial milestone payments from Jazz, with the next milestone being an IND clearance from this program from the US Food and Drug Administration. Redx is also eligible for tiered, mid-single digit percentage royalties based on any future net sales. As part of a separate collaboration agreement, signed in parallel, Jazz will pay Redx to perform research and preclinical development activities with the goal of completing IND-enabling studies for both KRAS profiles. |
Kelonia Therapeutics, Xyphos Biosciences | Feb 2024 | 875 | Research and licensing agreement for immuno-oncology therapeutics | Astellas Pharma and Kelonia Therapeutics announced that Xyphos Biosciences and Kelonia have entered into a research collaboration and license agreement to develop novel Immuno-Oncology therapeutics. Under the terms of the agreement, the companies plan to combine Kelonia's iGPS with Xyphos' ACCEL technology to develop innovative in vivo CAR-T Cell therapies*2 targeting up to two programs. Xyphos will be responsible for the development and commercialization of products created from the collaborative research. Kelonia will receive US $40 million upfront for the first program, and an additional US $35 million should Xyphos exercise its options for the second program, and potential milestones and contingency payments approaching US $800 million in total. Kelonia will receive R&D funding for work performed in the collaboration and is eligible for tiered royalties on net sales up to the double digit percentage. |
Boehringer Ingelheim, Sosei Heptares | Mar 2024 | 825.4 | Licensing agreement for G protein-coupled receptor target portfolio of GPR52 agonists. | Boehringer Ingelheim is paying €25 million ($27.3 million) upfront further milestone payments of up to €670 million ($732.6 million) in a deal with Sosei Heptares to develop potential first-in-class treatments targeting all symptoms of schizophrenia Under the agreement, Boehringer Ingelheim has the exclusive option to license Sosei Heptares’ portfolio of GPR52 agonists, which are a G protein-coupled receptor target. Sosei is also eligible for an option payment of €60 million ($65.5 million) and possible development, regulatory and commercialization milestone payments. The London-based pharma, whose parent company is Japan’s Sosei Group Corporation, will also net customary tiered royalties on future product sales. Boehringer will have the exclusive option to license the portfolio of GPR 52 agonists after the completion of Sosei’s Phase I and Phase Ib trials and Phase II enabling activities with the antipsychotic HTL0048149. Sosei will retain control and sponsor the trials until the potential option is exercised, which is estimated to occur in 2025. The portfolio that Boehringer gains will include the HTL’149 asset and other “differentiated backup compounds” that are designed by Sosei. |
Peak Rock Capital, Steris Corporation | Apr 2024 | 800 | Asset and equity purchase agreement for STERIS dental segment | STERIS to sell dental segment to an affiliate of Peak Rock Capital Transaction expected to close in STERIS’s first quarter of fiscal 2025 Divestiture allows STERIS to focus on Customers within core markets Proceeds primarily to be used to repay debt Transaction is structured as an equity sale STERIS has entered a definitive agreement to divest its Dental segment to Peak Rock Capital for $787.5 million Transaction terms also include the opportunity for STERIS to receive an additional earnout of up to $12.5 million, subject to the achievement of certain revenue targets of the Dental segment in fiscal 2025 |
Elektrofi, Janssen Biotech | Jan 2024 | 793 | Collaboration and licensing agreement for subcutaneous version of a lead oncology asset | Elektrofi has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech. This collaboration will initially focus on developing an at home self-administered subcutaneous version of a lead oncology asset. The agreement was facilitated by Johnson & Johnson Innovation. Elektrofi will receive an upfront payment of $18 million in exchange for Janssen receiving the exclusive right to a lead Janssen oncology target and up to four additional targets. Elektrofi will be eligible to receive future milestones surpassing $155 million per target, subject to achieving developmental, regulatory, and sales-based milestones, as well as a tiered upper mid-single digit royalty on global net sales for commercialized products. Janssen will be responsible for each product’s clinical development and commercialization. |
TreeFrog Therapeutics, Vertex Pharmaceuticals | Apr 2024 | 780 | Collaboration and licensing agreement for C-Stem manufacturing technology in type 1 diabetes | Vertex obtains an exclusive license to TreeFrog's C-Stem manufacturing technology in type 1 diabetes TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells TreeFrog will receive a $25M upfront payment plus equity investment $215M in milestones paid in connection with the development of a scaled-up process for fully differentiated islet cells TreeFrog is also eligible to receive an additional $540M in clinical, regulatory and commercial milestones on up to two future products Tiered single digit royalties Vertex will fund all research and development costs related to the collaboration Vertex will be responsible for all development and commercialization of its cell therapies |
C4 Therapeutics, Merck KGaA | Mar 2024 | 756 | Discovery research collaboration and licensing agreement for targeted protein degraders against critical oncogenic proteins | Collaboration Focused on Two Targeted Protein Degraders from C4T’s Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery Research Costs Under the Collaboration C4T Eligible for up to Approximately $740 Million in Discovery, Development and Commercial Milestone Payments, in Addition to Future Royalties, Across Entire Collaboration C4T is eligible for mid-single to low-double digit tiered royalties on future sales for each program Merck KGaA, Darmstadt, Germany, will be responsible for clinical development and commercialization for drug candidates coming out of these programs |
BridGene Biosciences, Galapagos | Jan 2024 | 727 | Collaboration and licensing agreement for small molecule drug discovery in oncology | Galapagos has entered into a strategic collaboration and licensing agreement with BridGene Biosciences. Galapagos and BridGene aim to discover and develop new precision medicines against clinically validated oncology targets by leveraging Galapagos’ expertise in small molecule drug discovery and translational research along with BridGene’s proprietary IMTAC chemoproteomics platform. The parties will advance the molecules into clinical candidates, and Galapagos has exclusive rights for further development and commercialization of any product candidates developed under the agreement. BridGene will receive from Galapagos up to $27 million in upfront and preclinical research milestone payments and potentially over $700 million in clinical and commercial milestones, assuming success of the programs. BridGene will be entitled to receive single-digit tiered royalties on net sales of each product resulting from the collaboration. |
Abbvie, OSE Immunotherapeutics | Feb 2024 | 713 | Development and licensing agreement for OSE-230 | AbbVie and OSE Immunotherapeutics announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage. AbbVie will receive an exclusive global license to develop, manufacture and commercialize OSE-230. OSE Immunotherapeutics will receive a $48 million upfront payment and will be eligible to receive up to an additional $665 million in clinical development, regulatory and commercial milestones. OSE Immunotherapeutics will be eligible to receive potential tiered royalties on global net sales of OSE-230. |
3D Medicines, Alphamab Oncology, Glenmark Pharmaceuticals S.A. | Jan 2024 | 700.8 | Licensing agreement for KN035 | Alphamab Oncology and 3DMedicines entered into a license agreement with Glenmark Specialty for the subcutaneous injection PD-L1 antibody drug (R&D code: KN035, generic name: Envafolimab), pursuant to which, Glenmark was granted exclusive licensing interests in clinical development and commercialization of oncology indications in India, Asia Pacific(except Singapore, Thailand, Malaysia), the Middle East and Africa, Russia, CIS and Latin America. Glenmark will develop and commercialize KN035 in the Field in the Territory at its own cost and expense. Licensors will receive from GSSA (a) a total of up to US$700.8 million of a non-refundable upfront payment and milestones payments subject to the achievement of certain development, regulatory and commercialization milestones, and (b) a single to double digits percentage royalty fee according to the level of net sales of KN035. The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between Jiangsu Alphamab and 3D Medicines. Jiangsu Alphamab retains its sole right to manufacture KN035 for any purpose within or outside the Territory. 3D Medicines retains the right to develop and commercialize KN035 for any purpose in the field of tumor outside the Territory. |
Johnson Matthey, Montagu Private Equity | Mar 2024 | 700 | Asset purchase agreement for medical device components business | Johnson Matthey Plc signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity for cash consideration of US$700 million (£550 million) on a cash free debt free basis
The gross assets that are the subject of this transaction amounted to £60 million as at 30th September 2023 For the financial year ended 31st March 2023, these assets generated reported profit before tax of £17 million Proceeds after tax and divestment costs for the disposal of MDC are expected to be c.£450 million |
Bristol-Myers Squibb, VantAI | Feb 2024 | 674 | Collaboration, option and licensing agreement for molecular glue drug discovery through artificial intelligence | VantAI and Bristol Myers Squibb have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest. The partnership leverages VantAI's geometric deep learning capabilities with Bristol Myers Squibb’s expertise in targeted protein degradation to discover and develop new small molecule therapeutics. The collaboration will focus on leveraging VantAI’s generative AI platform to design molecular glues as small molecule therapeutics. These efforts advance VantAI's mission to unlock the potential of proximity modulation as a powerful tool against therapeutic targets. VantAI is eligible to receive up to $674 million in discovery, development, clinical, regulatory, and sales milestone payments plus tiered royalties from Bristol Myers Squibb, with an option to further expand to additional therapeutic programs. |
Gilead Sciences, Xilio Therapeutics | Mar 2024 | 647.5 | License agreement for Phase 1 tumor-activated IL-12 program, XTX301 | Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio’s tumor-activated IL-12 Xilio will receive $43.5 million in upfront payments, including a cash payment of $30.0 million and an initial equity investment by Gilead of $13.5 million in Xilio common stock at a premium Xilio will be eligible to receive up to $604.0 million in additional contingent payments, including additional equity investments by Gilead, a transition fee and specified development, regulatory and sales-based milestones Xilio will also be eligible to receive tiered royalties ranging from high single digits to mid-teens on annual global net product sales Xilio will be responsible for conducting clinical development of XTX301 in the ongoing Phase 1 clinical trial through dose expansion Following the delivery by Xilio of a specified clinical data package for XTX301, Gilead can elect to transition responsibilities for the development and commercialization of XTX301 to Gilead, subject to the terms of the agreement and payment by Gilead of a $75 million transition fee Prior to the potential transition fee, Xilio is eligible to receive up to a total of $29.0 million in additional equity investments and a development milestone payment Gilead does not exclude acquired IPR&D expenses from its non-GAAP financial measures This transaction is expected to reduce Gilead’s GAAP and non-GAAP 2024 EPS by approximately $0.03 – $0.04 |
GenEdit, Genentech | Jan 2024 | 644 | Collaboration and licensing agreement for nanoparticles to deliver genetic medicines for autoimmune disease | GenEdit announced a multiyear collaboration and license agreement with Genentech. The companies will employ GenEdit’s NanoGalaxy platform to discover and develop novel nanoparticles to deliver Genentech’s nucleic acid-based medicines for treatment of autoimmune disease. GenEdit will collaborate with Genentech to discover and develop hydrophilic nanoparticles that can be used to develop nucleic acid-based medicines for autoimmune indications. Genentech will be responsible for preclinical, clinical, and regulatory development as well as commercialization of products resulting from the use of GenEdit’s nanoparticles. GenEdit will receive an upfront payment of $15 million and is eligible to receive up to $629 million in near-term, preclinical and clinical development, commercial, and net sales milestone payments over the course of the collaboration as well as tiered royalties on global net sales for resulting products. |
Allorion Therapeutics, AstraZeneca | Jan 2024 | 540 | Option and licensing agreement for L858R allosteric inhibitor program | Allorion Therapeutics has entered into an exclusive option and global license agreement with AstraZeneca to develop and commercialize a novel epidermal growth factor receptor L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer. AstraZeneca will be granted an exclusive option to license a novel EGFR L858R allosteric inhibitor to develop and commercialize globally. Allorion is eligible to receive upfront and near-term payments of up to $40 million, and additional development and commercial milestone payments of over $500 million, as well as tiered royalties on net sales worldwide. |
3T Biosciences, Boehringer Ingelheim | Jan 2024 | 538.5 | Collaboration and licensing agreement for next-generation life-changing cancer immunotherapies | Boehringer Ingelheim Pharmaceuticals and 3T Biosciences have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies. This second research partnership with 3T builds on the successful completion of the initial research partnership announced last year by the two companies. It brings together 3T's best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim's commitment to develop first-in-class immuno-oncology treatments that boost the immune system's ability to recognize, attack and kill tumors. Boehringer Ingelheim will provide patient-derived T-cell receptor data to fuel 3T's target discovery efforts to identify cognate antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones for both agreements totaling $538.5 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement. |
Menarini, Stemline Therapeutics | Jan 2024 | 500 | Licensing agreement for small molecule KAT6A inhibitor | Menarini Group and Stemline Therapeutics have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico’s AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications. Stemline will provide a $12 million upfront payment to Insilico. The combined value of the deal, including all development, regulatory, and commercial milestones, is over $500 million, followed by royalties up to double digits. |